Tuberculosis remains primary cause of comparatively high mortality worldwide. The statistics highlighted that three million people worldwide die annually from complication of TB and there are estimated 8 million of new cases each year, and today more people die from tuberculosis than ever before. In recent history, however, poor compliance with the prolonged and complicated chemotherapeutic regimens currently used to treat the disease, in conjunction with the advent of the AIDS epidemic and the increased mobility of human populations, has led to the emergence of numerous multidrug resistant Mycobacterium tuberculosis strain. The aim of this review is to showcase treatment of tuberculosis in HIV patients.

This review has been aimed at the treatment of rheumatoid arthritis and their significance. Rheumatoid arthritis is the most important systemic disease. The current review information has been found to reveal both remarkable active medicine and a variety of valuable practical applications. An interest in the exploration of this medicine has undoubtedly been growing due to their proven utility as attractive lead structures for the design of novel agents with a mechanism of action that sometimes differs from that of clinically authorized current antirheumatic drugs. Therefore, in the present review work we have focussed our attention on the information revealing rheumatoid arthritis treatment.

A series of Ethyl-3-methyl-5-(substituted-phenyl)-6,7,8,9-tetrahydro-5H-thiazolo 2,3-b]quinazoline-2-carboxylate derivatives have been synthesize from cyclohexanone and substituted benzaldehyde with the aim of developing potential antimicrobials and antitubercular agents. It was characterized by FT-IR, 1H NMR and Mass spectroscopy. All the newly synthesized compounds were screened for their antimicrobial and antifungal activities on Staphylococcus aureus, Staphylococcus epidermidis, Micrococcus luteus, Bacillus cereus (Gram-positive bacteria), Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumonia (Gram-negative bacteria), Aspergillus fumigates, Candida albicans (Fungi). All the synthesized compounds were also evaluated for their antitubercular activity against Mycobacterium tuberculosis strain H37Ra.